Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Cape Town, South Africa.
Department of Nuclear Medicine, University College Hospital, Ibadan, Oyo State, Nigeria.
Cancer Imaging. 2024 Apr 1;24(1):46. doi: 10.1186/s40644-024-00693-9.
PSMA PET/CT is the most sensitive molecular imaging modality for prostate cancer (PCa), yet much of the developing world has little or no access to PET/CT. [Tc]Tc-PSMA scintigraphy (PS) is a cheaper and more accessible gamma camera-based alternative. However, many resource-constrained departments have only a single camera without tomographic or hybrid imaging functionality, and camera time is frequently in high demand. Simplifying imaging protocols by limiting the field of view (FOV) and omitting SPECT/CT or even SPECT may provide a partial solution. The aim was thus to determine the adequacy of PS planar-only and/or SPECT-only imaging protocols with a limited FOV.
The scans of 95 patients with histologically proven PCa who underwent PS with full-body planar and multi-FOV SPECT/CT were reviewed. The detection rates for uptake in the prostate gland/bed and in metastases were compared on planar, SPECT, and SPECT/CT. The agreement between modalities was calculated for the detection of metastases and for staging. The impact of imaging a limited FOV was determined.
Pathological prostatic uptake was seen in all cases on SPECT/CT (excluding two post-prostatectomy patients), 90.3% of cases on SPECT, and 15.1% on planar images (p < 0.001). Eleven (11.7%) patients had seminal vesicle involvement on SPECT/CT, which was undetectable/indistinguishable on planar images and SPECT. The agreement between modalities was moderate to good (κ = 0.41 to 0.61) for the detection of nodal metastases, with detection rates that did not differ significantly (SPECT/CT = 11.6%, SPECT = 8.4%, planar = 5.3%). Detection rates for bone metastases were 14.7% (SPECT/CT) and 11.6% (SPECT and planar). Agreement between modalities for the detection of bone metastases was good (κ = 0.73 to 0.77). Three (3.1%) patients had visceral metastases on SPECT/CT, two of which were detected on SPECT and planar. There was good agreement between modalities for the TNM staging of patients (κ = 0.70 to 0.88). No metastatic lesions were missed on the limited FOV images.
When PS scintigraphy is performed, SPECT/CT is recommended. However, the lack of SPECT/CT capabilities should not preclude the use of PS in the presence of limited resources, as both planar and SPECT imaging are adequate and will correctly stage most PCa patients. Furthermore, time-based optimisations are achievable by limiting the FOV to exclude the distal lower limbs.
PSMA PET/CT 是前列腺癌(PCa)最敏感的分子成像方式,但世界上许多发展中国家几乎无法获得 PET/CT。[Tc]Tc-PSMA 闪烁显像(PS)是一种更便宜、更容易获得的伽马相机替代方法。然而,许多资源有限的部门只有一台没有断层或混合成像功能的相机,而且相机时间经常需求量很大。通过限制视野(FOV)并省略 SPECT/CT 甚至 SPECT 来简化成像方案可能是一个部分解决方案。因此,本研究旨在确定具有有限 FOV 的 PS 平面单光子发射计算机断层扫描(SPECT)和 SPECT 仅成像方案的充分性。
回顾了 95 例经组织学证实的前列腺癌患者的 PS 全身平面和多 FOV SPECT/CT 扫描。比较了前列腺/床和转移灶摄取的平面、SPECT 和 SPECT/CT 检测率。计算了各种模式在检测转移灶和分期方面的一致性。确定了成像有限 FOV 的影响。
SPECT/CT 上均可见所有病例的病理性前列腺摄取(排除 2 例前列腺切除术后患者),90.3%的病例在 SPECT 上,15.1%的病例在平面图像上(p<0.001)。11 例(11.7%)患者在 SPECT/CT 上有精囊受累,而在平面图像和 SPECT 上无法检测到/难以区分。各模式间检测淋巴结转移的一致性为中等至良好(κ=0.41 至 0.61),检测率无显著差异(SPECT/CT=11.6%,SPECT=8.4%,平面=5.3%)。骨转移的检测率为 14.7%(SPECT/CT)和 11.6%(SPECT 和平面)。各模式间骨转移的检测一致性良好(κ=0.73 至 0.77)。3 例(3.1%)患者在 SPECT/CT 上有内脏转移,其中 2 例在 SPECT 和平面上检测到。各模式对患者 TNM 分期的一致性良好(κ=0.70 至 0.88)。在有限的 FOV 图像上未遗漏任何转移性病变。
当进行 PS 闪烁显像时,推荐使用 SPECT/CT。然而,在资源有限的情况下,缺乏 SPECT/CT 功能不应排除 PS 的使用,因为平面和 SPECT 成像均足够,并且可以正确分期大多数 PCa 患者。此外,通过将 FOV 限制在排除远端下肢来实现基于时间的优化。